Cambridge, 17 October 2016 ... The number of datasets discoverable through the Repositive platform has now reached over one million, making Repositive the world’s largest portal for accessing human genomic data.
Repositive, a software company developing novel tools to improve access to human genomic research data, has expanded the number of datasets now available on its free platform to include 1,006,914 datasets from 32 different global data sources.
The Repositive team has been expanding the range of datasets available by incorporating public data, privately held data, and has continued to add specialist dataset collections including Chinese control data, Methylation data and Expression data.
Alongside the specialized dataset collections, Repositive has also created a pre-competitive consortium with Astra Zeneca. The consortium will develop a resource for streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) in oncology research. To find out more about this consortium and how to join visit https://repositive.io/pdx
Fiona Nielsen, CEO of Repositive said: “Over a million datasets is a significant landmark for Repositive. However, sheer quantity of data is often not enough, so we have invested considerably in helping the scientific community to identify and use the most relevant and high quality data for their research.”
This latest news builds on a number of other key developments during 2016. The company has launched an upgraded platform, raised additional seed funding of £500,000, secured partnerships and with AstraZeneca and Xpressomics and won the Pistoia Alliance inaugural President’s Start Up Challenge.
Repositive, a software company developing novel tools to improve access to human genomic research data, has expanded the number of datasets now available on its free platform to include 1,006,914 datasets from 32 different global data sources.
The Repositive team has been expanding the range of datasets available by incorporating public data, privately held data, and has continued to add specialist dataset collections including Chinese control data, Methylation data and Expression data.
Alongside the specialized dataset collections, Repositive has also created a pre-competitive consortium with Astra Zeneca. The consortium will develop a resource for streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) in oncology research. To find out more about this consortium and how to join visit https://repositive.io/pdx
Fiona Nielsen, CEO of Repositive said: “Over a million datasets is a significant landmark for Repositive. However, sheer quantity of data is often not enough, so we have invested considerably in helping the scientific community to identify and use the most relevant and high quality data for their research.”
This latest news builds on a number of other key developments during 2016. The company has launched an upgraded platform, raised additional seed funding of £500,000, secured partnerships and with AstraZeneca and Xpressomics and won the Pistoia Alliance inaugural President’s Start Up Challenge.
